Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gain Therapeutics, Inc. - Common Stock (NQ:GANX)

1.800 +0.060 (+3.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gain Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
Via Get News
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
--News Direct-- 
Via News Direct
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
Bethesda, MD, August 29, 2023 (PlatoData via 500NewsWire) -- Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies,... 
Via TheNewswire.com
Expert Ratings for Gain Therapeutics
Via Benzinga
Chardan Capital Maintains Buy Rating for Gain Therapeutics: Here's What You Need To Know
Via Benzinga
Where Gain Therapeutics Stands With Analysts
Via Benzinga
Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson’s Disease and Movement Disorders®
From Gain Therapeutics, Inc.
Via GlobeNewswire
Analyst Expectations for Gain Therapeutics's Future
Via Benzinga
Expert Ratings for Gain Therapeutics
Via Benzinga
Analyst Ratings for Gain Therapeutics
Via Benzinga
Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Present at the Jefferies Healthcare Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting
Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer’s disease 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders
Panel, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, March 29, 2023 at 12:00 pm ET 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program
Grant awarded to consortium led by Gain Therapeutics to advance the development of proprietary allosteric small molecule regulators against Alpha-1 Antitrypsin (AAT) Deficiency 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium
Study results support the disease-modifying potential of GCase-targeting small molecule therapy for neuronopathic Gaucher disease 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences
Gain to present new preclinical data on its lead programs in GBA1-related diseases 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Medtronic To $85? Plus Oppenheimer Slashes PT On This Stock By 67%
  
Via Benzinga
Heska To $165? Plus BTIG Cuts PT On This Stock By 67%
BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ: GANX) from $30 to $10. BTIG analyst Thomas Shrader maintained a Buy rating on the stock. Gain Therapeutics shares rose 1.3% to close at... 
Via Benzinga
AMD To Rally Around 39%? Here Are 5 Other Price Target Changes For Monday
Baird raised Advanced Micro Devices, Inc. (NASDAQ: AMD) price target from $65 to $100. . Baird analyst Tristan Gerra upgraded the stock from Neutral to Outperform. AMD shares rose 5.7% to close at... 
Via Benzinga
Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.